Form 8-K - Current report:
SEC Accession No. 0001213900-25-050055
Filing Date
2025-06-02
Accepted
2025-06-02 16:22:10
Documents
15
Period of Report
2025-05-30
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0244195-8k_cero.htm   iXBRL 8-K 39044
2 EMPLOYMENT AGREEMENT BY AND BETWEEN CERO THERAPEUTICS HOLDINGS, INC., AND CHRIS ea024419501ex10-1_cero.htm EX-10.1 32797
3 EMPLOYMENT AGREEMENT BY AND BETWEEN CERO THERAPEUTICS HOLDINGS, INC., AND ANDREW ea024419501ex10-2_cero.htm EX-10.2 24505
  Complete submission text file 0001213900-25-050055.txt   327338

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE cero-20250530.xsd EX-101.SCH 3809
5 XBRL DEFINITION FILE cero-20250530_def.xml EX-101.DEF 26680
6 XBRL LABEL FILE cero-20250530_lab.xml EX-101.LAB 36816
7 XBRL PRESENTATION FILE cero-20250530_pre.xml EX-101.PRE 25304
17 EXTRACTED XBRL INSTANCE DOCUMENT ea0244195-8k_cero_htm.xml XML 5946
Mailing Address 201 HASKINS WAY SUITE 230 SOUTH SAN FRANCISCO CA 94080
Business Address 201 HASKINS WAY SUITE 230 SOUTH SAN FRANCISCO CA 94080 650-407-2376
CERO THERAPEUTICS HOLDINGS, INC. (Filer) CIK: 0001870404 (see all company filings)

EIN.: 871088814 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40877 | Film No.: 251015273
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)